* Date : 2020-11-26
Recent announcements from Pfizer and Moderna have raised hopes about a possible COVID-19 vaccine. Both companies said their vaccines had proven to be more than 90 percent effective in clinical trials, but it’s still unclear when they will become available. How many does are needed, and how long will the protection last? Meanwhile, wealthy nations have purchased more than half of the promised doses of leading vaccine candidates, triggering a debate over equal access to vaccines. In this week’s edition of Foreign Correspondents, we sit down with our panel of journalists to talk more about questions and concerns surrounding vaccine development.
- Jack Barton / Freelance Journalist
- Stanislav Varivoda, Correspondent / TASS
- Josh Smith, Senior Correspondent / Reuters
Skype Interview Guests
- Jerome Kim, Director General / International Vaccine Institute